37.35
前日終値:
$38.10
開ける:
$37.95
24時間の取引高:
832.92K
Relative Volume:
0.67
時価総額:
$7.31B
収益:
$29.52M
当期純損益:
$-567.06M
株価収益率:
-10.20
EPS:
-3.66
ネットキャッシュフロー:
$-551.11M
1週間 パフォーマンス:
-1.99%
1か月 パフォーマンス:
-4.43%
6か月 パフォーマンス:
-15.44%
1年 パフォーマンス:
+15.89%
Revolution Medicines Inc Stock (RVMD) Company Profile
名前
Revolution Medicines Inc
セクター
電話
415-766-3638
住所
700 SAGINAW DR, REDWOOD CITY, CA
RVMD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RVMD
Revolution Medicines Inc
|
37.35 | 7.31B | 29.52M | -567.06M | -551.11M | -3.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-07-16 | 繰り返されました | Needham | Buy |
2024-07-12 | 開始されました | Barclays | Overweight |
2024-07-08 | 開始されました | Jefferies | Buy |
2024-04-12 | 繰り返されました | Needham | Buy |
2024-04-10 | アップグレード | Raymond James | Outperform → Strong Buy |
2024-03-11 | 開始されました | Piper Sandler | Overweight |
2024-01-05 | アップグレード | BofA Securities | Neutral → Buy |
2024-01-04 | 開始されました | Wedbush | Outperform |
2023-11-16 | 開始されました | Raymond James | Outperform |
2023-02-28 | アップグレード | JP Morgan | Neutral → Overweight |
2022-12-14 | 開始されました | Needham | Buy |
2022-10-21 | 開始されました | Oppenheimer | Outperform |
2022-05-20 | 開始されました | BofA Securities | Neutral |
2022-03-01 | アップグレード | Stifel | Hold → Buy |
2021-09-23 | 開始されました | Stifel | Hold |
2021-08-12 | ダウングレード | Goldman | Buy → Neutral |
2021-05-18 | 開始されました | Goldman | Buy |
2020-05-21 | 開始されました | H.C. Wainwright | Buy |
2020-03-09 | 開始されました | Cowen | Outperform |
2020-03-09 | 開始されました | Guggenheim | Buy |
2020-03-09 | 開始されました | JP Morgan | Neutral |
すべてを表示
Revolution Medicines Inc (RVMD) 最新ニュース
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock By Investing.com - Investing.com South Africa
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock - Investing.com
Revolution Medicines executive sells shares worth $128,598 By Investing.com - Investing.com Australia
Revolution Medicines’ general counsel sells $56,920 in stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock By Investing.com - Investing.com Australia
Revolution Medicines CFO Jack Anders sells $72,771 in stock By Investing.com - Investing.com Canada
Revolution Medicines’ general counsel sells $56,920 in stock - Investing.com India
Revolution Medicines CFO Jack Anders sells $72,771 in stock - Investing.com
Revolution Medicines Executives Sell Shares - TradingView
Revolution Medicines Inc (RVMD) Should Be Considered For The Next Few Weeks - Stocks Register
Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 20 - GuruFocus.com
Revolution Medicines at Leerink Conference: Expanding RAS Inhibitor Reach By Investing.com - Investing.com Canada
Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com Canada
Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa
Revolution Medicines at Barclays Conference: Focus on Pancreatic Cancer Trials - Investing.com UK
Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs - TipRanks
HC Wainwright Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - Defense World
Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now - Yahoo Finance
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Revolution Medicines’ (RVMD) “Outperform” Rating Reiterated at Wedbush - Armenian Reporter
Long Term Trading Analysis for (RVMD) - Stock Traders Daily
Wedbush Reaffirms Outperform Rating for Revolution Medicines (NASDAQ:RVMD) - Defense World
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Revolution stock price target cut to $59 at Needham - Investing.com
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Revolution Medicines Reports 2024 Financial Results and Progress - TipRanks
Earnings call transcript: Revolution Medicines Q4 2024 reflects strategic advancements - Investing.com India
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress - GlobeNewswire
Revolution Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Revolution Medicines Q4 Net Loss Narrows -February 26, 2025 at 05:13 pm EST - Marketscreener.com
Earnings Flash (RVMD) Revolution Medicines Q4 Loss of $1.12 per Share vs. FactSet Est Loss of $0.99 - Marketscreener.com
Revolution Medicines, Inc. SEC 10-K Report - TradingView
Can Revolution Medicines' $2.3B War Chest Overcome Mounting Losses in Cancer Drug Race? - StockTitan
Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 2024 Result - Yahoo Finance
Revolution Medicines to Participate in March 2025 Investor Conferences - The Manila Times
Can Revolution Medicines' Triple Conference Appearance Signal Major Clinical Updates? - StockTitan
Rhumbline Advisers Acquires 24,473 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers | Journal of Medicinal Chemistry - ACS Publications
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $66.25 Consensus Target Price from Brokerages - Defense World
Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday - Defense World
Revolution Medicines to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Nasdaq
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - The Manila Times
Revolution Medicines to Report Financial Results for Fourth - GlobeNewswire
Revolution Medicines Q4 Earnings Coming: Will Their Cancer Drug Pipeline Show Progress? - StockTitan
Revolution Medicines Inc (RVMD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):